Show simple item record

dc.contributor.authorOwens, S E
dc.contributor.authorThatcher, Nick
dc.contributor.authorSharma, H
dc.contributor.authorAdam, N
dc.contributor.authorHarrison, R
dc.contributor.authorSmith, A
dc.contributor.authorZaki, A
dc.contributor.authorBaer, J C
dc.contributor.authorMcAuliffe, C A
dc.contributor.authorCrowther, Derek
dc.date.accessioned2010-07-21T10:36:50Z
dc.date.available2010-07-21T10:36:50Z
dc.date.issued1985
dc.identifier.citationIn vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera. 1985, 14 (3):253-7 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704
dc.identifier.pmid3888431
dc.identifier.doi10.1007/BF00258128
dc.identifier.urihttp://hdl.handle.net/10541/108012
dc.description.abstractThe in vivo distribution in man of the four platinum derivatives cis-dichlorodiammine platinum(II) (DDP), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV) (CHIP), cis-dichloro-bis-cyclopropylamine platinum(II) (CP), and cis-diammine 1, 1-cyclobutanedicarboxylate platinum(II) (CBDCA) has been observed. The availability of these compounds labelled with the radioactive isotope of platinum, platinum-191, has made serial in vivo imaging of their distribution possible. Injection of 17-35 MBq (5-28 mg) of the labelled compound IV was followed by imaging, using a gamma camera, with particular reference to the kidneys, liver, and tumour site. Hepatic and renal clearances were observed in all nine patients, but no unequivocal evidence of tumour uptake was found. The left kidney uptake was estimated at times up to 7 days after injection. Mathematical analysis of some of the uptake curves failed to show any significant difference between the clearance times observed. However, the two patients who received CBDCA did show a higher initial renal uptake, falling within the 1st day to levels comparable with those of the other compounds, and the three patients who received DDP showed consistently liver uptake.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAdult
dc.subject.meshAntineoplastic Agents
dc.subject.meshCarboplatin
dc.subject.meshCisplatin
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshRadionuclide Imaging
dc.subject.meshTissue Distribution
dc.titleIn vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.en
dc.typeArticleen
dc.contributor.departmentRegional Department of Medical Physics and Bioengineering, Christie Hospital and Holt Radium Institute, Withington, M20 9BX Manchester, England.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen
html.description.abstractThe in vivo distribution in man of the four platinum derivatives cis-dichlorodiammine platinum(II) (DDP), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (IV) (CHIP), cis-dichloro-bis-cyclopropylamine platinum(II) (CP), and cis-diammine 1, 1-cyclobutanedicarboxylate platinum(II) (CBDCA) has been observed. The availability of these compounds labelled with the radioactive isotope of platinum, platinum-191, has made serial in vivo imaging of their distribution possible. Injection of 17-35 MBq (5-28 mg) of the labelled compound IV was followed by imaging, using a gamma camera, with particular reference to the kidneys, liver, and tumour site. Hepatic and renal clearances were observed in all nine patients, but no unequivocal evidence of tumour uptake was found. The left kidney uptake was estimated at times up to 7 days after injection. Mathematical analysis of some of the uptake curves failed to show any significant difference between the clearance times observed. However, the two patients who received CBDCA did show a higher initial renal uptake, falling within the 1st day to levels comparable with those of the other compounds, and the three patients who received DDP showed consistently liver uptake.


This item appears in the following Collection(s)

Show simple item record